Dr. Reddy';s Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market

Rhea-AI Summary

Dr. Reddy's Laboratories Ltd. has launched Pemetrexed for Injection in 100 mg and 500 mg single-dose vials, approved by the USFDA. This generic version is an equivalent to ALIMTA®, which generated approximately $1.24 billion in US sales for the twelve months ending March 2022. The introduction of this generic product expands Dr. Reddy's offerings in oncology and positions the company in a significant market segment, potentially benefiting its financial growth.

Positive

• Launch of Pemetrexed for Injection enhances product portfolio in oncology.
• Approval by USFDA positions Dr. Reddy's favorably in the competitive generics market.
• Access to a market with approximately $1.24 billion in annual sales increases revenue potential.

Negative

• None.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of ALIMTA® (pemetrexed for injection) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).

The ALIMTA® brand and generic had U.S. sales of approximately $1239 million MAT for the most recent twelve months ending in March 2022 according to IQVIA Health*.

Dr. Reddy’s Pemetrexed for Injection is supplied in 100 mg and 500 mg single-dose vials.

Click here for full prescribing information.

ALIMTA is a trademark of Eli Lilly and Company

*IQVIA Retail and Non-Retail MAT March 2022

RDY-0522-413

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005288/en/

AMIT AGARWAL

AMITA@DRREDDYS.COM



USHA IYER

USHAIYER@DRREDDYS.COM

Source: Dr. Reddy’s Laboratories Ltd.

FAQ

What is the significance of Dr. Reddy's new Pemetrexed product launch?

The launch of Pemetrexed for Injection allows Dr. Reddy's to enter a market with significant sales potential, given that ALIMTA® generated approximately $1.24 billion in US sales.

When was Pemetrexed for Injection approved by the USFDA?

Pemetrexed for Injection was approved by the USFDA and announced on the date of the press release.

What are the available dosages for Dr. Reddy's Pemetrexed for Injection?

Dr. Reddy's Pemetrexed for Injection is available in 100 mg and 500 mg single-dose vials.

How does Pemetrexed for Injection compare to ALIMTA® in terms of market potential?

Pemetrexed for Injection is the generic equivalent of ALIMTA®, which had US sales of approximately $1.24 billion for the twelve months ending March 2022.

What impact might this product launch have on Dr. Reddy's stock?

The product launch could positively impact Dr. Reddy's stock by increasing revenue from a large market segment in oncology.